Handelsbanken Fonder Ab Amarin Corp Plcuk Transaction History

Handelsbanken Fonder Ab

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$1.07 - $1.34 $33,598 - $42,076	-31,400 Reduced 48.31%	33,600 $41,000
Q1 2022 May 11, 2022	SELL	$2.85 - $3.73 $138,225 - $180,905	-48,500 Reduced 42.73%	65,000 $214,000
Q4 2021 Feb 08, 2022	BUY	$3.24 - $5.18 $69,660 - $111,370	21,500 Added 23.37%	113,500 $382,000
Q2 2021 Aug 03, 2021	BUY	$4.26 - $6.5 $122,262 - $186,550	28,700 Added 45.34%	92,000 $403,000
Q4 2020 Feb 11, 2021	SELL	$4.04 - $5.31 $161,196 - $211,868	-39,900 Reduced 38.66%	63,300 $310,000
Q3 2020 Nov 13, 2020	BUY	$3.64 - $7.76 $76,076 - $162,184	20,900 Added 25.39%	103,200 $434,000
Q2 2020 Aug 13, 2020	BUY	$4.78 - $8.26 $393,394 - $679,798	82,300 New	82,300 $570,000

177

65.1M

258K

98K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $202M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.